The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, Jonsson Comprehensive Cancer Center at UCLA, elaborates on promising developments in the second-line treatment of hepatocellular carcinoma (HCC) and provides an overview of the CheckMate 040 trial and KEYNOTE-240 from the 2021 Gastrointestinal Cancers Symposium
Tags: ASCO GI Conference CoverageLiver (includes HCC, Billiary Tract)
Published: 21 January 2021
Kathy Oubre, MS, considers how comfortable physicians and payers are with biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, considers how comfortable physicians and payers are with biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, considers how comfortable physicians and payers are with biosimilars
Kathy Oubre, MS, speculates on the future of biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, speculates on the future of biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, speculates on the future of biosimilars
Kathy Oubre, MS, offers opinion on whether biosimilars are living up to their estimated cost savings
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, offers opinion on whether biosimilars are living up to their estimated cost savings
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, offers opinion on whether biosimilars are living up to their estimated ...
Kathy Oubre, MS, comments on the recent criticism regarding the use of biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, comments on recent criticisms surrounding biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, comments on recent criticisms surrounding biosimilars
Bo Gamble, on the most important critical success factors when adopting a new payment model
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when adopting a new payment model
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when ...
Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice can remain efficient and sensitive to patients who have just received a cancer diagnosis
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice ...
Bo Gamble, discusses the impact of consolidation on the delivery of cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer care and on alterative payment models (APMs)
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer ...
Bo Gamble, speculates on the future of alternative payment models (APMs)
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and explains how a practice can determine which APMs are most appropriate to pursue
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and ...
Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of ...
Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care
Kathy Oubre, MS, comments on the recent criticism regarding the use of biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, comments on recent criticisms surrounding biosimilars
Kathy Oubre, MS, offers opinion on whether biosimilars are living up to their estimated cost savings
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, offers opinion on whether biosimilars are living up to their estimated cost savings
Kathy Oubre, MS, speculates on the future of biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, speculates on the future of biosimilars
Kathy Oubre, MS, considers how comfortable physicians and payers are with biosimilars
Kathy Oubre, MS, Chief Executive Officer, Pontchartrain Cancer Center, considers how comfortable physicians and payers are with biosimilars
Bo Gamble, considers how value & quality may vary across community oncology practices
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, considers how the concepts of value and quality may vary across community oncology practices
Alti Rahman, MHA\MBA, CSSBB, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, regarding the impact of consolidation on the delivery of cancer care
Alti Rahman, MHA\MBA, CSSBB, offers advice to oncology practices in today's cancer care landscape
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, offers advice to oncology practices looking to succeed in today's landscape of cancer care
Bo Gamble, speculates on the future of alternative payment models (APMs)
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, speculates on the future of alternative payment models (APMs) and explains how a practice can determine which APMs are most appropriate to pursue
Bo Gamble, discusses the impact of consolidation on the delivery of cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, discusses the impact of consolidation on the delivery of cancer care and on alterative payment models (APMs)
Alti Rahman, MHA\MBA, CSSBB, reflects on social determinants of health in cancer care
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, reflects on social determinants of health and considers how an oncology practice can remain efficient and sensitive to patients who have just received a cancer diagnosis
Bo Gamble, on the most important critical success factors when adopting a new payment model
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, offers opinion on the most important critical success factors when adopting a new payment model
Alti Rahman, MHA\MBA, CSSBB, provides perspective on the challenges facing oncology practices
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, provides perspective on some of the biggest challenges currently facing oncology practices
Alti Rahman, MHA\MBA, CSSBB, considers how oncology practices can reduce costs & maximize savings
Alti Rahman, MHA\MBA, CSSBB, Practice Administrator, Oncology Consultants, discusses some of the best practices for oncology practices to help reduce costs and maximize savings
Bo Gamble, compares and contrasts the definition of value and quality as it relates to cancer care
Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance, compares and contrasts the definition of value and quality as it relates to cancer care
Johnetta Blakely, MD, explains the role of HEOR as it contributes to value-based care
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, explains the role of health economics outcomes research (HEOR) as it contributes to value-based care
Johnetta Blakely, MD, considers how HEOR data influences payer decisions
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, considers how health economics and outcomes research (HEOR) data influences payer decisions
Johnetta Blakely, MD, elaborates on how HEOR may be used in conjunction with real-world evidence
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, elaborates on how health economics outcomes research (HEOR) may be used in conjunction with artificial intelligence and/or real-world evidence
Johnetta Blakely, MD, offers an example of how HEOR has impacted cancer care at Tennessee Oncology
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, offers a case example of how real-world evidence and health economics outcomes research (HEOR) have made an impact on the quality and cost of cancer care at Tennessee Oncology
Johnetta Blakely, MD, reflects on the progress and innovation of community oncologists
Dr. Blakely, Executive Director of Health Economics Outcomes Research (HEOR), Tennessee Oncology, considers the progress being made at the community level in providing cancer patients with access to innovative therapies and quality of care while reducing cost
Jonathan E. Levitt, Esq., offers opinion on PBM consolidation & the changing dynamics of cancer care
Jonathan E. Levitt, Esq., Co-Founding Partner, Frier Levitt, offers opinion on PBM consolidation and the changing dynamics of cancer care
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.